NewAmsterdam Pharma Company NAMS Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's total liabilities & equity?
- NewAmsterdam Pharma Company (NAMS) reported total liabilities & equity of $732.64M in Q1 2026.
- How has NewAmsterdam Pharma Company's total liabilities & equity changed year-over-year?
- NewAmsterdam Pharma Company's total liabilities & equity decreased by 10.5% year-over-year, from $818.41M to $732.64M.
- What is the long-term trend for NewAmsterdam Pharma Company's total liabilities & equity?
- Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's total liabilities & equity has grown at a 17.1% compound annual growth rate (CAGR), from $478.5M to $769.28M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.